ModifiedBlue Cross Blue Shield - OklahomaPolicy CPCPLAB049

General Inflammation Testing (CRP and ESR) Reimbursement

This policy governs BCBSOK reimbursement criteria for measurement of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for inflammatory conditions and general inflammation testing for covered members and providers.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyGeneral Inflammation Testing (CRP and ESR) Reimbursement

Policy CodePolicy CPCPLAB049

Change TypeRevisions to reimbursement table, test preference, and frequency guidancenew non‑reimbursement rule for ESR

Effective DateNov 1, 2023

Next Review DateN/A

Key ActionSubmit accurate documentation upon request; note that ESR is not reimbursable without a diagnosed inflammatory condition and CRP is preferred where indicated.

SourceLink

POLICY UPDATE CHANGES

Reimbursement information revised to provide specific listing of inflammatory conditions for ESR, CRP or both ESR/CRP testing including frequency.

CRP is listed first due to preference for CRP over ESR.

For individuals without a diagnosed inflammatory condition, measurement of erythrocyte sedimentation rate (ESR) is not reimbursable.

Frequency guidance for Acute Hematogenous Osteomyelitis (AHO) and Giant Cell Arteritis (GCA) updated to specify timing (to confirm diagnosis; 2–3 days early therapeutic course; weekly until normalization for AHO; and to confirm diagnosis and during follow-up visits for GCA).

Table 1 introductory statement updated to indicate CRP can be conventional or high-sensitivity.

3primary reimbursement rules listed

~30+

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

conditions in Table 1

3procedure codes listed

AddedESR excluded without diagnosis

PreferenceCRP preferred

Coverage Criteria for CRP and ESR

CRP/ESR coverage criteria

Measurement of CRP and/or ESR may be reimbursable when used for specific diagnosed or suspected inflammatory conditions as designated in Table 1. Testing is not reimbursable in certain scenarios.

CRP and/or ESR may be reimbursable for inflammatory conditions listed in Table 1; see Table 1 for condition-specific test preference and suggested frequency.

For individuals without a diagnosed inflammatory condition, measurement of erythrocyte sedimentation rate (ESR) is not reimbursable.

Measurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable.

Table 1 details: Condition-specific preferences and suggested frequencies (examples): Acute Hematogenous Osteomyelitis — CRP preferred; serial testing to confirm diagnosis, 2–3 days during early therapy, then weekly until normalization or clear trend toward normalization. Giant Cell Arteritis — CRP and ESR to confirm diagnosis and during follow-up visits. Rheumatoid Arthritis — CRP or ESR prior to treatment, every 1–3 months during active disease, annually when disease is inactive.

Not all requirements apply to every product; providers should review applicable plan documents for eligible coverage.

Coverage criteria summary

Reimbursement and frequency guidance was revised to specify which inflammatory conditions warrant ESR, CRP, or both; to prefer CRP where appropriate; and to exclude ESR reimbursement when no diagnosed inflammatory condition is present.

Policy updated to list CRP first due to preference for CRP over ESR.

New non-reimbursement rule: For individuals without a diagnosed inflammatory condition, measurement of ESR is not reimbursable.

Table 1 introductory statement clarified that CRP may be conventional or high-sensitivity for purposes of the guidance.

Frequency guidance clarified for select conditions: Acute Hematogenous Osteomyelitis (to confirm diagnosis; 2–3 days during early therapeutic course; weekly until normalization or clear trend toward normalization) and Giant Cell Arteritis (to confirm diagnosis; during follow-up visits).

Inclusion of a procedure code in the policy does not guarantee coverage; claims remain subject to edits and applicable contract/plan terms.

Procedure Coding

Example procedure codes (not all-inclusive)CPT

85651	Erythrocyte sedimentation rate
85652	Erythrocyte sedimentation rate, automated
86140	C-reactive protein (CRP)

Provider Actions and Reimbursement Rules

Documentation Required

Documentation and claim review — submit accurate records and expect requests for supporting documentation

Providers must submit accurate documentation of services performed and may be asked to provide additional documentation upon request; claims are subject to code edit protocols and claim review against plan documents, provider contracts, medical policies, and coding policies.

Submit claims using HIPAA-approved code sets and industry coding guidelines (UB, AMA CPT, HCPCS, ICD-10, NDC, DRG, CMS/NCCI).
Be prepared to supply additional documentation when requested during claim review.

Billing Rule

Reimbursement rules and test frequency — ESR not reimbursable without diagnosis; prefer CRP

ESR testing is not reimbursable for individuals without a diagnosed inflammatory condition; CRP is listed first and preferred in the reimbursement guidance. The reimbursement table was clarified to specify condition‑specific test preferences and updated frequency guidance for select conditions.

Definitions and Plan Requirements

Plan documents

Governing documentsCertificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents govern in the event of a conflict with this policy; plan documents will control coverage determinations.

Contract precedenceIf a conflict arises between this Clinical Payment and Coding Policy and a provider contract, the provider contract will govern.

BCBSOK discretionBCBSOK may use reasonable discretion in interpreting and applying this policy and has final discretionary authority to the extent provided under applicable plan documents.

Provider actionProviders should review applicable plan documents for eligible coverage as not all requirements apply to each product.

Provider coding expectations

Required code sets

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyGeneral Inflammation Testing (CRP and ESR) Reimbursement

Policy CodePolicy CPCPLAB049

Change TypeRevisions to reimbursement table, test preference, and frequency guidancenew non‑reimbursement rule for ESR

Effective DateNov 1, 2023

Next Review DateN/A

Key ActionSubmit accurate documentation upon request; note that ESR is not reimbursable without a diagnosed inflammatory condition and CRP is preferred where indicated.

SourceLink

On This Page

Do not bill ESR for members who do not have a diagnosed inflammatory condition — such ESR testing is not reimbursable.
Order CRP (conventional or high‑sensitivity) where the table indicates preference; CRP is listed first due to preference over ESR.
Follow the table’s specified testing frequencies for conditions (examples updated include AHO and GCA).

Claims must be submitted using valid code combinations from HIPAA‑approved code sets (e.g., CPT, HCPCS, ICD‑10).

Coding guidelinesProviders are expected to code appropriately per industry standards including UB Editor, AMA CPT, CPT Assistant, NDC, DRG, and CMS/NCCI guidance.

Claim edits and reviewClaims are subject to code edit protocols and review against benefit terms, provider contracts, medical policies, and coding software logic.

Documentation requirementUpon request, providers are urged to submit any additional documentation to support claims.

CRP assay types

Assay types coveredCRP is recognized as either conventional CRP or high‑sensitivity CRP and the table guidance was updated to indicate this explicitly.

Test preferencePolicy language places preference on CRP over ESR where applicable (CRP listed first in reimbursement guidance).

Table labelingTable 1 introductory statement specifies coverage of ESR, CRP (conventional or high‑sensitivity), or both based on the diagnosed or suspected inflammatory condition.